Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 0.55 |
| ▸ | MAP4K1 | Q92918 | 17/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651299 | 1.00 | ALK (0.55) | ALKMAP4K1PTK2 | |
| SCHEMBL29651119 | 0.94 | ALK (0.57) | ALKMAP4K1PTK2 | |
| SCHEMBL22864728 | 0.94 | ALK (0.57) | ALKMAP4K1PTK2 | |
| SCHEMBL22864477 | 0.90 | MAP4K1 (0.55) | ALKMAP4K1PTK2 | |
| SCHEMBL29651271 | 0.90 | MAP4K1 (0.55) | ALKMAP4K1PTK2 | |
| SCHEMBL22864628 | 0.89 | MAP4K1 (0.57) | ALKMAP4K1PTK2 | |
| SCHEMBL29651332 | 0.89 | MAP4K1 (0.57) | ALKMAP4K1PTK2 | |
| SCHEMBL22864689 | 0.88 | MAP4K1 (0.55) | ALKMAP4K1PTK2 | |
| SCHEMBL22864471 | 0.87 | MAP4K1 (0.62) | ALKMAP4K1 | |
| SCHEMBL29651250 | 0.87 | MAP4K1 (0.62) | ALKMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2021000935-A1 | HPK1 INHIBITORS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | ALK 4067/4885MAP4K1 63/4885PTK2 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.